epirubicin , which is now in phase iii clinical development , has been shown to possess a better therapeutic index than doxorubicin since it induces less acute toxicities ( nausea and vomiting , mucositis , myelosuppression ) and less cardiotoxicity than its parent compound , without loss of activity in responsive tumours .
C0014582
epirubicin
C0013089
doxorubicin